http://www.bloodcmecenter.org/ en-us Education The Blood CME Center podcast series brings expert advice, opinion, and education to your computer or personal audio device. Subscribe to the Blood CME Center podcast series and stay up-to-date on issues relating to acquired coagulopathy and trauma-related operative hemostasis. Blood CME Center, BloodCMECenter.org, CME, Hemostasis, Cardiovascular and Metabolic Health Foundation, Health, Education, Medicine http://www.BloodCMECenter.org/feed/300x300-bloodCMEcenterLogo.jpg http://www.BloodCMECenter.org - FeedForAll Podcasting no http://www.bloodcmecenter.org/LcDetails.aspx?AID=65 http://www.bloodcmecenter.org/LcDetails.aspx?AID=65 Wednesday, 9 February 2011 In this Q&A podcast activity, blood oncology expert Sagar Lonial, MD, discusses how physicians and nurses can manage comorbidities and adverse events in multiple myeloma patients. 00:30:05 Managing Multiple Myeloma Patients' Comorbidities and Adverse Events Associated With Treatment In this Q&A podcast activity, blood oncology expert Sagar Lonial, MD, discusses how physicians and nurses can manage comorbidities and adverse events in multiple myeloma patients. Educational Concepts in Medicine http://www.bloodcmecenter.org/LcDetails.aspx?AID=45 http://www.bloodcmecenter.org/LcDetails.aspx?AID=45 Tuesday, 6 April 2010 11:30:53 -0400 In this podcast, we interview hemophilia experts Michael Recht, Associate Professor of Pediatrics and Medicine and Director of The Hemophilia Center at Oregon Health & Science University in Portland, Oregon, and Guy Young, Director of the Hemostasis and Thrombosis Center Children’s Hospital and Associate Professor of Pediatrics at USC Keck School of Medicine in Los Angeles, California. Drs. Recht and Young provide expert commentary on issues such as the role of prophylaxis therapy in hemophilia treatment; the benefits of prophylaxis with bypassing agents in patients with inhibitors; and an effective treatment algorithm for the initiation of prophylactic bypassing therapy. 00:28:13 Prophylactic Bypassing Therapy in Hemophilia Patients With Inhibitors—Expert Commentary In this podcast, we interview hemophilia experts Michael Recht, Associate Professor of Pediatrics and Medicine and Director of The Hemophilia Center at Oregon Health & Science University in Portland, Oregon, and Guy Young, Director of the Hemostasis and Thrombosis Center Children’s Hospital and Associate Professor of Pediatrics at USC Keck School of Medicine in Los Angeles, California. Drs. Recht and Young provide expert commentary on issues such as the role of prophylaxis therapy in hemophilia treatment; the benefits of prophylaxis with bypassing agents in patients with inhibitors; and an effective treatment algorithm for the initiation of prophylactic bypassing therapy. Educational Concepts in Medicine http://www.bloodcmecenter.org/LcDetails.aspx?AID=38 http://www.bloodcmecenter.org/LcDetails.aspx?AID=38 Friday, 11 December 2009 11:30:53 -0400 In this podcast, Listen to expert commentary derived from the symposium titled Multidisciplinary Team Care in Hemophilia: Elective Orthopedic Surgery in Patients With Inhibitors, which was held at the National Hemophilia Foundation (NHF) Annual Meeting on October 31, 2009. In this podcast activity, James Munn, RN, MS, and Angela Forsyth, PT, DPT, offer their perspective as team members of hemophilia treatment center (HTC) programs. Each clinician addresses the specific needs of hemophilia A patients with inhibitors who elect to undergo orthopedic surgery and the challenges faced by the HTC team as a result of that decision. 00:31:13 Elective Orthopedic Surgery in Patients With Inhibitors: Preoperative and Postoperative Care In this podcast, Listen to expert commentary derived from the symposium titled Multidisciplinary Team Care in Hemophilia: Elective Orthopedic Surgery in Patients With Inhibitors, which was held at the National Hemophilia Foundation (NHF) Annual Meeting on October 31, 2009. In this podcast activity, James Munn, RN, MS, and Angela Forsyth, PT, DPT, offer their perspective as team members of hemophilia treatment center (HTC) programs. Each clinician addresses the specific needs of hemophilia A patients with inhibitors who elect to undergo orthopedic surgery and the challenges faced by the HTC team as a result of that decision. Educational Concepts in Medicine http://www.bloodcmecenter.org/LcDetails.aspx?AID=44 http://www.bloodcmecenter.org/LcDetails.aspx?AID=44 Fri, 26 February 2010 11:30:53 -0400 Is fibrinogen deficiency a fundamental risk factor for cardiac surgery? In an interview with Blood CME Center staff, Aryeh Shander, MD, FCCM, FCCP, offers his expert opinion on the role of fibrinogen in surgical hemostasis. As part of his discussion, Dr. Shander reflects on recent data correlating fibrinogen levels with the risk of bleeding, particularly in the cardiac surgery population, as well as current and emerging strategies for achieving and maintaining optimal hemostasis. 00:17:34 Current Trends in Coagulation: The Correlation Between Fibrinogen Levels and Surgical Hemostasis Is fibrinogen deficiency a fundamental risk factor for cardiac surgery? In an interview with Blood CME Center staff, Aryeh Shander, MD, FCCM, FCCP, offers his expert opinion on the role of fibrinogen in surgical hemostasis. As part of his discussion, Dr. Shander reflects on recent data correlating fibrinogen levels with the risk of bleeding, particularly in the cardiac surgery population, as well as current and emerging strategies for achieving and maintaining optimal hemostasis. Educational Concepts in Medicine http://www.bloodcmecenter.org/LcDetails.aspx?AID=40 http://www.bloodcmecenter.org/LcDetails.aspx?AID=40 Mon, 21 December 2009 11:30:53 -0400 Are there hemostatic challenges unique to cardiac surgery? An anesthesiologist and a surgeon discuss important factors in perioperative cardiac bleeding and the clinician's ability to mitigate against those factors in this informative Q&A exchange. Topics covered include strategies for managing hemostasis; the debate concerning optimal fibrinogen levels; benefits and drawbacks to using allogeneic blood products for the correction of low fibrinogen levels; how to measure clot formation intraoperatively and postoperatively; as well as recent developments in point-of-care diagnostics, including ROTEM, and how these developments likely will impact the perioperative management of hemostasis. 00:17:00 Q&A: Challenges in Perioperative Hemostasis: Managing Coagulopathy in Elective and Urgent Cardiac Surgery Are there hemostatic challenges unique to cardiac surgery? An anesthesiologist and a surgeon discuss important factors in perioperative cardiac bleeding and the clinician's ability to mitigate against those factors in this informative Q&A exchange. Topics covered include strategies for managing hemostasis; the debate concerning optimal fibrinogen levels; benefits and drawbacks to using allogeneic blood products for the correction of low fibrinogen levels; how to measure clot formation intraoperatively and postoperatively; as well as recent developments in point-of-care diagnostics, including ROTEM, and how these developments likely will impact the perioperative management of hemostasis. Educational Concepts in Medicine http://www.bloodcmecenter.org/LcDetails.aspx?AID=37 http://www.bloodcmecenter.org/LcDetails.aspx?AID=37 Thursday, 10 December 2009 11:30:53 -0400 In this Q&A podcast activity, Paul G. Richardson, MD, is interviewed on the latest advances in multiple myeloma treatment, including immunomodulatory drugs that target the bone marrow microenvironment, optimal timing for stem cell harvesting, and promising agents currently under investigation. 00:21:48 Improving Survival in Patients With Multiple Myeloma: New Treatment Options and Therapeutic Combinations In this Q&A podcast activity, Paul G. Richardson, MD, is interviewed on the latest advances in multiple myeloma treatment, including immunomodulatory drugs that target the bone marrow microenvironment, optimal timing for stem cell harvesting, and promising agents currently under investigation. Educational Concepts in Medicine http://www.bloodcmecenter.org/LcDetails.aspx?AID=35 http://www.bloodcmecenter.org/LcDetails.aspx?AID=35 Monday, 11 November 2009 11:30:53 -0400 In this Q&A podcast activity, blood oncology expert Mecide M. Gharibo, MD, reflects on how the advent of novel agents and treatment strategies has revolutionized the treatment of multiple myeloma. Dr. Gharibo specifically discusses the impact of new and emerging therapies, the value of combination treatment, and the importance of individualizing treatment in the management of multiple myeloma. 00:16:58 Meeting the Challenges of Multiple Myeloma: Targeting Therapy. . .Optimizing Outcomes In this Q&A podcast activity, blood oncology expert Mecide M. Gharibo, MD, reflects on how the advent of novel agents and treatment strategies has revolutionized the treatment of multiple myeloma. Dr. Gharibo specifically discusses the impact of new and emerging therapies, the value of combination treatment, and the importance of individualizing treatment in the management of multiple myeloma. Educational Concepts in Medicine http://www.bloodcmecenter.org/LcDetails.aspx?AID=31 http://www.bloodcmecenter.org/LcDetails.aspx?AID=31 Thursday, 15 October 2009 11:30:53 -0400 In this learning activity, blood oncology expert and NCCN Multiple Myeloma Panel member William Bensinger, MD, discusses topics such as individualized treatment strategies, the impact of emerging therapies, and the value of combination treatment in the management of multiple myeloma. The emergence of numerous therapies in recent years has led to significant advances in the treatment of multiple myeloma. Dr. Bensinger draws upon his clinical expertise to discuss how these emerging therapies and the current standards of care may be employed to enhance patient outcomes and improve survival. 00:23:21 Diagnostic Indicators and Clinical Challenges of Multiple Myeloma In this learning activity, blood oncology expert and NCCN Multiple Myeloma Panel member William Bensinger, MD, discusses topics such as individualized treatment strategies, the impact of emerging therapies, and the value of combination treatment in the management of multiple myeloma. The emergence of numerous therapies in recent years has led to significant advances in the treatment of multiple myeloma. Dr. Bensinger draws upon his clinical expertise to discuss how these emerging therapies and the current standards of care may be employed to enhance patient outcomes and improve survival. Educational Concepts in Medicine http://www.bloodcmecenter.org/HemophiliaCenter.aspx http://www.bloodcmecenter.org/HemophiliaCenter.aspx Fri, 10 December 2009 11:30:53 -0400 Listen to expert commentary derived from the symposium titled "Multidisciplinary Team Care in Hemophilia: Elective Orthopedic Surgery in Patients With Inhibitors," which was held at the National Hemophilia Foundation (NHF) Annual Meeting on October 31, 2009. In this podcast activity, James Munn, RN, MS, and Angela Forsyth, PT, DPT, offer their perspective as team members of hemophilia treatment center (HTC) programs. Each clinician addresses the specific needs of hemophilia A patients with inhibitors who elect to undergo orthopedic surgery and the challenges faced by the HTC team as a result of that decision. 00:31:12 Elective Orthopedic Surgery in Patients With Inhibitors: Preoperative and Postoperative Care Listen to expert commentary derived from the symposium titled "Multidisciplinary Team Care in Hemophilia: Elective Orthopedic Surgery in Patients With Inhibitors," which was held at the National Hemophilia Foundation (NHF) Annual Meeting on October 31, 2009. In this podcast activity, James Munn, RN, MS, and Angela Forsyth, PT, DPT, offer their perspective as team members of hemophilia treatment center (HTC) programs. Each clinician addresses the specific needs of hemophilia A patients with inhibitors who elect to undergo orthopedic surgery and the challenges faced by the HTC team as a result of that decision. Educational Concepts in Medicine http://www.bloodcmecenter.org/LcDetails.aspx?AID=23 http://www.bloodcmecenter.org/LcDetails.aspx?AID=23 Mon, 27 July 2009 11:30:53 -0400 Trauma surgeons Bryan A. Cotton and Martin A. Schreiber participate in a Q&A exchange on conventional and emerging strategies for managing the coagulopathy of trauma. Long regarded as iatrogenic in nature, the coagulopathy of trauma is now being recognized as a condition that occurs almost immediately following injury. In this podcast activity, Drs. Cotton and Schreiber draw on their many years of combined experience in trauma and critical care surgery to field questions on such issues as clinician perceptions regarding trauma coagulopathy, treatment protocols, blood product ratios, and future directions in trauma care. 00:14:16 Q&A: Current Protocols and Future Strategies for Managing the Coagulopathy of Trauma Trauma surgeons Bryan A. Cotton and Martin A. Schreiber participate in a Q&A exchange on conventional and emerging strategies for managing the coagulopathy of trauma. Long regarded as iatrogenic in nature, the coagulopathy of trauma is now being recognized as a condition that occurs almost immediately following injury. In this podcast activity, Drs. Cotton and Schreiber draw on their many years of combined experience in trauma and critical care surgery to field questions on such issues as clinician perceptions regarding trauma coagulopathy, treatment protocols, blood product ratios, and future directions in trauma care. Educational Concepts in Medicine http://www.bloodcmecenter.org/LcDetails.aspx?AID=22 http://www.bloodcmecenter.org/LcDetails.aspx?AID=22 Fri, 30 June 2009 11:30:53 -0400 Trauma anesthesiologist Richard P. Dutton, MD, MBA, draws on his clinical experiences at the R Adams Cowley Shock Trauma Center, the largest-volume trauma center in the United States, to discuss the coagulopathy of trauma and the ways in which treatment strategies for this condition have evolved over time. Clinicians’ understanding of the coagulopathy of trauma has advanced over the past 5 to 10 years. In this podcast activity, Dr. Dutton specifically addresses the early coagulopathy of trauma as a distinct entity, damage control surgery, resuscitation strategies and the use of antifibrinolytic therapies, and the future role of recombinant factor VIIa in resuscitation and coagulopathy. 00:09:11 Q&A Evolving Strategies in the Treatment of the Coagulopathy of Trauma Trauma anesthesiologist Richard P. Dutton, MD, MBA, draws on his clinical experiences at the R Adams Cowley Shock Trauma Center, the largest-volume trauma center in the United States, to discuss the coagulopathy of trauma and the ways in which treatment strategies for this condition have evolved over time. Clinicians’ understanding of the coagulopathy of trauma has advanced over the past 5 to 10 years. In this podcast activity, Dr. Dutton specifically addresses the early coagulopathy of trauma as a distinct entity, damage control surgery, resuscitation strategies and the use of antifibrinolytic therapies, and the future role of recombinant factor VIIa in resuscitation and coagulopathy. Educational Concepts in Medicine http://www.bloodcmecenter.org/LcDetails.aspx?AID=21 http://www.bloodcmecenter.org/LcDetails.aspx?AID=21 Fri, 29 May 2009 11:30:53 -0400 In this Q&A interview, Aryeh Shander, MD, FCCM, FCCP, discusses the challenges that preoperative anemia presents to surgical team members and other clinicians. As part of this podcast, Dr. Shander addresses the association between outcomes and etiology of anemia, the importance of low hemoglobin level and symptoms in the treatment of preoperative anemia, and therapeutic choices for patients with preoperative anemia that is associated with chronic comorbidities such as kidney disease, HIV, and sickle cell disease. 00:19:20 Q&A Pressing Issues About Preoperative Anemia In this Q&A interview, Aryeh Shander, MD, FCCM, FCCP, discusses the challenges that preoperative anemia presents to surgical team members and other clinicians. As part of this podcast, Dr. Shander addresses the association between outcomes and etiology of anemia, the importance of low hemoglobin level and symptoms in the treatment of preoperative anemia, and therapeutic choices for patients with preoperative anemia that is associated with chronic comorbidities such as kidney disease, HIV, and sickle cell disease. Educational Concepts in Medicine http://www.bloodcmecenter.org/LcDetails.aspx?AID=11 http://www.bloodcmecenter.org/LcDetails.aspx?AID=11 Tuesday, 2 June 2009 11:30:53 -0400 Listen to John B. Holcomb, MD, FACS, a Trauma Consultant for the Surgeon General, discuss the potential consequences of traumatic combat injury and the measures taken to prevent these consequences. As part of his discussion, Dr. Holcomb describes the differences between current and past patterns of combat injury, the signs and symptoms of hemorrhagic shock, and the effects of various types of transfusion and other treatments. 00:12:22 Q&A Coagulopathy in Trauma Listen to John B. Holcomb, MD, FACS, a Trauma Consultant for the Surgeon General, discuss the potential consequences of traumatic combat injury and the measures taken to prevent these consequences. As part of his discussion, Dr. Holcomb describes the differences between current and past patterns of combat injury, the signs and symptoms of hemorrhagic shock, and the effects of various types of transfusion and other treatments. Educational Concepts in Medicine http://www.bloodcmecenter.org/LcDetails.aspx?AID=19 http://www.bloodcmecenter.org/LcDetails.aspx?AID=19 Fri, 29 May 2009 11:30:53 -0400 Trauma anesthesiologist Richard P. Dutton, MD, MBA, addresses a series of questions on the mechanistic theory of coagulopathy, evolving resuscitation techniques, and recent changes in the way clinicians regard the early coagulopathy of trauma. Hemorrhage is a major contributor to the dilemma of traumatic injury and its subsequent care, and patients with massive traumatic hemorrhage inevitably develop coagulopathy. More than 80% of the trauma deaths that occur in the OR do so as a result of hemorrhage. The acquired coagulopathy of trauma is an important clinical issue that continues to be studied and debated. 00:19:20 Q&What Makes Trauma Patients Coagulopathic? Trauma anesthesiologist Richard P. Dutton, MD, MBA, addresses a series of questions on the mechanistic theory of coagulopathy, evolving resuscitation techniques, and recent changes in the way clinicians regard the early coagulopathy of trauma. Hemorrhage is a major contributor to the dilemma of traumatic injury and its subsequent care, and patients with massive traumatic hemorrhage inevitably develop coagulopathy. More than 80% of the trauma deaths that occur in the OR do so as a result of hemorrhage. The acquired coagulopathy of trauma is an important clinical issue that continues to be studied and debated. Educational Concepts in Medicine http://www.bloodcmecenter.org/LcDetails.aspx?AID=16 http://www.bloodcmecenter.org/LcDetails.aspx?AID=16 Mon, 11 May 2009 11:30:53 -0400 Blood management expert Jerrold Levy, MD, FAHA, addresses questions concerning today's therapeutic options for achieving and maintaining intraoperative hemostasis. As part of this activity, Dr. Levy discusses current recommendations for selecting topical agents and the value of hemostatic tests both inside and outside of the OR. Additional topics discussed by Dr. Levy include the clinical significance of acquired coagulopathy secondary to bovine thrombin exposure, individual dynamics that may predispose a patient to intraoperative bleeding, and the challenges of maintaining hemostasis in the surgical setting. 00:19:10 Q&A Hemostatic Agents Blood management expert Jerrold Levy, MD, FAHA, addresses questions concerning today's therapeutic options for achieving and maintaining intraoperative hemostasis. As part of this activity, Dr. Levy discusses current recommendations for selecting topical agents and the value of hemostatic tests both inside and outside of the OR. Additional topics discussed by Dr. Levy include the clinical significance of acquired coagulopathy secondary to bovine thrombin exposure, individual dynamics that may predispose a patient to intraoperative bleeding, and the challenges of maintaining hemostasis in the surgical setting. Educational Concepts in Medicine http://www.bloodcmecenter.org/LcDetails.aspx?AID=18 http://www.bloodcmecenter.org/LcDetails.aspx?AID=18 Fri, 8 May 2009 11:30:53 -0400 Aryeh Shander, MD, FCCM, FCCP, addresses questions about acquired inhibitors to factor VIII and the clinical challenges presented by this coagulation disorder, particularly as it concerns elderly patients in the perioperative setting. Spontaneously acquired inhibitors to factor VIII occur rarely, with no known etiology in approximately half of all diagnosed cases. However, the majority of cases occur in older adults. In this Q&A podcast, Dr. Shander discusses the difficulties inherent in diagnosing acquired coagulopathies and treatment strategies specifically for managing acquired inhibitors to factor VIII. A case study complements this learning activity and reinforces key points raised in the Q&A. 00:19:10 Q&A Spontaneous Inhibitors to Factor VIII: Managing the Clinical Challenges of an Acquired Bleeding Disorder Aryeh Shander, MD, FCCM, FCCP, addresses questions about acquired inhibitors to factor VIII and the clinical challenges presented by this coagulation disorder, particularly as it concerns elderly patients in the perioperative setting. Spontaneously acquired inhibitors to factor VIII occur rarely, with no known etiology in approximately half of all diagnosed cases. However, the majority of cases occur in older adults. In this Q&A podcast, Dr. Shander discusses the difficulties inherent in diagnosing acquired coagulopathies and treatment strategies specifically for managing acquired inhibitors to factor VIII. A case study complements this learning activity and reinforces key points raised in the Q&A. Educational Concepts in Medicine http://www.bloodcmecenter.org/LcDetails.aspx?AID=9 http://www.bloodcmecenter.org/LcDetails.aspx?AID=9 Fri, 23 May 2008 11:30:53 -0400 Richard P. Dutton, MD, MBA; John B. Holcomb, MD, FACS; and Deborah M. Stein, MD, MPH, FACS, discuss the evolving clinical perceptions of acquired coagulopathy and how it is treated. As part of their discussion, these trauma specialists address the use of prohemostatic agents in military and civilian practice, hypotensive resuscitation practices, and standard procedures for utilizing off-label recombinant factor VIIa. 00:17:32 Q&A Discussion on Acquired Coagulopathy Richard P. Dutton, MD, MBA; John B. Holcomb, MD, FACS; and Deborah M. Stein, MD, MPH, FACS, discuss the evolving clinical perceptions of acquired coagulopathy and how it is treated. As part of their discussion, these trauma specialists address the use of prohemostatic agents in military and civilian practice, hypotensive resuscitation practices, and standard procedures for utilizing off-label recombinant factor VIIa. Educational Concepts in Medicine